This paradoxical increase in phosphorylation despite reduced total ERBB2 levels in the monotherapy groups may reflect a compensatory feedback activation, a phenomenon previously described in other tumor models exposed to targeted therapies [15,16]. The gene discussed is ERBB2; the disease is neoplasm.